Rosalind Advisors Inc. acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 260,000 shares of the company's stock, valued at approximately $3,149,000. Replimune Group comprises about 1.6% of Rosalind Advisors Inc.'s investment portfolio, making the stock its 18th biggest position. Rosalind Advisors Inc. owned approximately 0.38% of Replimune Group as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock valued at $5,313,000 after acquiring an additional 52,498 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock valued at $15,657,000 after purchasing an additional 217,308 shares during the period. Barclays PLC boosted its position in shares of Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock valued at $1,738,000 after purchasing an additional 98,791 shares in the last quarter. State Street Corp grew its stake in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Finally, Baker BROS. Advisors LP increased its holdings in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock worth $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.
Replimune Group Stock Down 2.7 %
Shares of Replimune Group stock traded down $0.29 during trading hours on Wednesday, reaching $10.40. The company's stock had a trading volume of 582,652 shares, compared to its average volume of 840,040. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a market capitalization of $800.96 million, a P/E ratio of -3.39 and a beta of 1.30. The stock's fifty day simple moving average is $12.67 and its two-hundred day simple moving average is $12.17. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have issued reports on REPL shares. JPMorgan Chase & Co. increased their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Jefferies Financial Group increased their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. BMO Capital Markets lifted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $19.43.
Get Our Latest Analysis on REPL
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Recommended Stories
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
